Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resveratrol Partners alleges false claims

This article was originally published in The Tan Sheet

Executive Summary

The maker of the resveratrol supplement Longevinex sues the reported owner of the Web site ResveratrolBenefits.com, identified as Jon Mayne, for allegedly making false and misleading statements about Longevinex. Mayne, which may be an alias, lists on his Web site Longevinex for more than twice the actual sale price, says it is "less effective" than other products and claims "there are no truly free trials of Longevinex available," according to Sept. 9 release from Resveratrol Partners, which filed the suit in Los Angeles federal court. The Las Vegas-based supplement maker notes Mayne's address is a United Parcel Service Store in San Francisco. It also maintains that ResveratrolBenefits.com links to Web sites that offer free products to consumers, but then charge their credit cards for unordered products. FTC is investigating these types of ads (1"The Tan Sheet" March 30, 2009)

You may also be interested in...



Acai Offered As Bait In Latest Marketing Scams To Draw Investigations

Trendy supplement ingredient acai is the latest lure in what the Federal Trade Commission calls "negative-option" online marketing scams

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel